For this experiment, we aimed to evaluate scCoVseq in human cells and minimize the often pronounced viral cytopathogenicity observed in Vero E6 cells; therefore, we infected the interferon-competent A549 human lung adenocarcinoma cell line (engineered to express the SARS-CoV-2 receptor, ACE2), with an attenuated mutant virus, recombinant SARS-CoV-2 (rSARS-CoV-2) ORF6 M58R, to allow for higher MOI infection without excessive cell death (44). This evidence concerns the gene ACE2 and lung adenocarcinoma.